持续动脉灌注化疗对中晚期口腔癌临床应用研究  

Clinical application of continuous arterial infusion chemotherapy in treatment for advanced oral cancer

作　　者：崔元 张婧 CUI Yuan;ZHANG Jing(Department of Stomatology,Huanghe S&T College Affiliated Hospital,Zhengzhou,Henan 450000,China;Department of Stomatology,the First Affiliated Hospital of Henan University,Kaifeng,Henan 475000,China)

机构地区：[1]黄河科技学院附属医院口腔科,河南郑州450000 [2]河南大学第一附属医院口腔科,河南开封475000

出　　处：《中国医学工程》2025年第4期82-86,共5页China Medical Engineering

摘　　要：目的观察持续动脉灌注化疗对中晚期口腔癌的治疗效果。方法该研究为前瞻性研究,研究对象为黄河科技学院附属医院2022年1月至2023年1月期间收治的93例中晚期口腔癌患者,应用电脑随机分组法将入组患者分别列为常规组(46例)和灌注组(47例),常规组实施手术治疗及术后化疗,灌注组在常规组的治疗基础上,采用持续动脉灌注新辅助化疗配合治疗,所有患者治疗后均随访1年,比较两组患者的近期疗效及短期预后情况。结果在不同治疗方案下,灌注组的甲胎蛋白(AFP)、组织多肽特异性抗原(TPS)、糖类抗原19-9(CA199)分别为(20.45±5.31)μg/L、(50.33±10.29)U/mL、(32.25±5.36)U/mL,均低于常规组[(23.49±5.25)μg/L、(55.45±10.28)U/mL、(35.44±5.28)U/mL](P<0.05);灌注组的客观缓解率(ORR)、疾病控制率(DCR)分别为85.11%(40/47)、91.49%(43/47),均高于常规组[65.22%(30/46)、69.57%(32/46)](P<0.05);灌注组治疗期间的不良反应发生率25.53%(12/47)与常规组21.74%(10/46)比较,差异无统计学意义(P>0.05);随访期间,灌注组的功能状态评分(KPS)、生活质量评分(QOL)分别为(85.49±10.25)分、(85.33±10.27)分,均高于常规组[(80.32±10.36)分、(80.31±10.52)分],体力状态评分(ZPS)[(1.36±0.33)分]低于常规组[(1.78±0.85)分](P<0.05);截至随访结束时,灌注组的中位无进展生存期(PFS)、中位总生存期(OS)分别为(9.33±1.26)个月、(10.47±2.25)个月,均高于常规组[(8.36±1.41)个月、(9.35±1.29)个月](P<0.05)。结论持续动脉灌注新辅助化疗能改善中晚期口腔癌患者的近期疗效,可在不明显增加化疗副反应发生风险的同时,有效改善患者短期预后。【Objective】To observe the therapeutic effect of continuous arterial infusion chemotherapy on advanced oral cancer.【Methods】This study was a prospective study,with 93 patients with advanced oral cancer admitted to Huanghe S&T College Affiliated Hospital from January 2022 to January 2023.The enrolled patients were randomly divided into a conventional group(46 cases)and a perfusion group(47 cases)using computer randomization.The conventional group received surgical treatment and postoperative chemotherapy,while the perfusion group received continuous arterial infusion neoadjuvant chemotherapy in combination with the conventional group.All patients were followed up for one year after treatment,and the shortterm efficacy and prognosis of the two groups were compared.【Results】Under different treatment plans,the AFP,TPS and CA199 of the perfusion group were 20.45±5.31μg/L,50.33±10.29 U/mL,and 32.25±5.36 U/mL,respectively,lower than those in the conventional group(23.49±5.25μg/L,55.45±10.28 U/mL,35.44±5.28 U/mL)(P<0.05).The ORR and DCR values of the perfusion group were 85.11%(40/47)and 91.49%(43/47),higher than those of the conventional group[65.22%(30/46)and 69.57%(32/46)](P<0.05).The incidence of adverse reactions during treatment in the perfusion group[25.53%(12/47)]was similar to the conventional group[21.74%(10/46)](P>0.05).During the follow-up period,the KPS and QOL scores of the perfusion group were 85.49±10.25 and 85.33±10.27,higher than those of the conventional group(80.32±10.36 and 80.31±10.52),and the ZPS score of the perfusion group(1.36±0.33)was lower than that of the conventional group(1.78±0.85)(P<0.05).As of the end of follow-up,the median PFS and median OS of the perfusion group were 9.33±1.26 months and 10.47±2.25 months,higher than those of the conventional group(8.36±1.41 months and 9.35±1.29 months)(P<0.05).【Conclusion】Continuous arterial infusion of neoadjuvant chemotherapy can improve the short-term efficacy of patients with advanced oral cancer,and effectively i

关 键 词：口腔癌 持续动脉灌注化疗 近期疗效 短期预后 

分 类 号：R739.8[医药卫生—肿瘤]